As EpiPen prices grew and grew and grew, it was increasingly American taxpayers that were footing the bill.

The share of revenue that big drug maker Mylan got for its life-saving EpiPen from taxpayers more than doubled in the past five years — a period when prices of the anti-allergy device climbed more than 350 percent, a US Senator said Thursday.

Sen. Chuck Grassley, R-Iowa, said his office compared newly released information from the government-run health coverage programs Medicare and Medicaid to Mylan’s filings with the Securities and Exchange Commission.

Read More

Related Articles